(Q37888659)

24 August 2017

1 reference

title

Molecular targeted therapy in ovarian cancer: what is on the horizon? (English)

1 reference

24 August 2017

1 reference

2

Bryan T Hennessy

1 reference

24 August 2017

Roshni Kalachand

1

1 reference

24 August 2017

Maurie Markman

series ordinal

3

1 reference

24 August 2017

publication date

1 May 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

71

1 reference

24 August 2017

issue

8

1 reference

24 August 2017

page(s)

947-967

1 reference

24 August 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

21 January 2018

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

21 January 2018

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

21 January 2018

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Inhibition of lysophosphatidic acid receptor-2 expression by RNA interference decreases lysophosphatidic acid-induced urokinase plasminogen activator activation, cell invasion, and migration in ovarian cancer SKOV-3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Why did p53 gene therapy fail in ovarian cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Protein kinase C iota: human oncogene, prognostic marker and therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

The biology of ovarian cancer: new opportunities for translation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

A novel amplification at 17q21-23 in ovarian cancer cell lines detected by comparative genomic hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Ovarian cancer: homeobox genes, autocrine/paracrine growth, and kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

The insulin-like growth factor-I receptor as a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Lysophosphatidic acid production and action: validated targets in cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

A genetically defined model for human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

PIK3CA is implicated as an oncogene in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

The biology and clinical relevance of the PTEN tumor suppressor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

E1A as a tumor suppressor gene: commentary re S. Madhusudan et al. A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HE

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Notch3 gene amplification in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Estrogen and progesterone receptors in ovarian epithelial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Significance of Fas receptor protein expression in epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

The role of c-FLIP(L) in ovarian cancer: chaperoning tumor cells from immunosurveillance and increasing their invasive potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Aurora-kinase inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Prognostic DNA methylation biomarkers in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591740-000000000-00000

Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth.

21 January 2018

1 reference

12 December 2020

Mutation of the PIK3CA gene in ovarian and breast cancer

1 reference

12 December 2020

Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites

1 reference

12 December 2020

Nuclear signaling by endothelin-1. A Ras pathway for activation of the c-fos serum response element

1 reference

12 December 2020

In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation.

1 reference

12 December 2020

Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells

1 reference

12 December 2020

Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer

1 reference

12 December 2020

A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts

1 reference

12 December 2020

Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas

1 reference

12 December 2020

Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers

1 reference

12 December 2020

Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients

1 reference

12 December 2020

Mutation and overexpression of p53 in early-stage epithelial ovarian cancer

1 reference

12 December 2020

Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract

1 reference

12 December 2020

Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics

1 reference

12 December 2020

In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002).

1 reference

12 December 2020

The genesis and evolution of high-grade serous ovarian cancer.

1 reference

12 December 2020

Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway

1 reference

12 December 2020

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

1 reference

12 December 2020

In situ human telomerase reverse transcriptase expression pattern in normal and neoplastic ovarian tissues.

1 reference

12 December 2020

PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer

1 reference

12 December 2020

Personalizing therapy for ovarian cancer: BRCAness and beyond

1 reference

12 December 2020

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.

1 reference

12 December 2020

Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma

1 reference

12 December 2020

A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies

1 reference

12 December 2020

Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase.

1 reference

12 December 2020

The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer.

1 reference

12 December 2020

Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins

1 reference

12 December 2020

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

1 reference

12 December 2020

10.2165/11591740-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

24 August 2017

1046763920

0 references

1 reference